NCR3 and rheumatoid arthritis: As represented in Figure 3B, when focusing on the activation marker Nkp30, we found significant differences between the RA patients treated with JAKis and those treated with bDMARDs and healthy controls in the percentage of activated NK Dim expressing Nkp30 (59.51 (32.19–80.34), 89.74 (84.81–95.81), and 85.28 (67.08–93.16), respectively (p values: <0.001 and 0.007).